EAM Investors LLC Sells 30,958 Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT)

EAM Investors LLC trimmed its holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 39.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,034 shares of the company's stock after selling 30,958 shares during the quarter. EAM Investors LLC owned about 0.17% of ClearPoint Neuro worth $739,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in CLPT. Barclays PLC increased its holdings in ClearPoint Neuro by 24.3% in the third quarter. Barclays PLC now owns 5,674 shares of the company's stock worth $64,000 after purchasing an additional 1,109 shares in the last quarter. LPL Financial LLC grew its position in shares of ClearPoint Neuro by 4.5% during the 4th quarter. LPL Financial LLC now owns 40,250 shares of the company's stock worth $619,000 after buying an additional 1,750 shares during the period. R Squared Ltd bought a new stake in shares of ClearPoint Neuro in the 4th quarter valued at $32,000. Parsons Capital Management Inc. RI lifted its position in shares of ClearPoint Neuro by 1.9% during the 4th quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company's stock valued at $2,177,000 after acquiring an additional 2,600 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of ClearPoint Neuro by 58.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock valued at $110,000 after acquiring an additional 3,612 shares during the period. Institutional investors own 30.08% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CLPT shares. Lake Street Capital upped their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday, January 21st. Stifel Nicolaus upped their price target on ClearPoint Neuro from $19.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Finally, B. Riley increased their price target on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th.

ClearPoint Neuro Stock Performance

Shares of NASDAQ CLPT remained flat at $12.80 during mid-day trading on Wednesday. 130,302 shares of the stock were exchanged, compared to its average volume of 221,685. The business has a fifty day moving average of $13.45 and a 200-day moving average of $14.04. The company has a market capitalization of $358.14 million, a PE ratio of -18.55 and a beta of 0.97. ClearPoint Neuro, Inc. has a 52-week low of $5.11 and a 52-week high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. The company had revenue of $7.77 million for the quarter, compared to the consensus estimate of $8.23 million. As a group, sell-side analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.